NASDAQ:ADGM Adagio Medical 5/15/2025 Earnings Report $1.40 -0.10 (-6.67%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$1.47 +0.07 (+5.00%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Adagio Medical EPS ResultsActual EPS-$0.51Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAdagio Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAdagio Medical Announcement DetailsQuarterDate5/15/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Adagio Medical Earnings HeadlinesAdagio Medical Holdings Inc. ADGM (U.S.: Nasdaq) - The Wall Street JournalJune 26, 2025 | wsj.comAdagio Medical Holdings, Inc. GAAP EPS of -$0.51May 16, 2025 | seekingalpha.comTurn $1K into $50K with This DeFi GemTHREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. | Crypto 101 Media (Ad)Adagio Medical Reports First Quarter 2025 ResultsMay 15, 2025 | businesswire.comAdagio Medical to Present at the BofA Securities 2025 Health Care ConferenceMay 7, 2025 | finance.yahoo.comAdagio Medical Holdings Appoints Interim CFO Daniel GeorgeApril 23, 2025 | tipranks.comSee More Adagio Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adagio Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagio Medical and other key companies, straight to your email. Email Address About Adagio MedicalAdagio Medical (NASDAQ:ADGM), Inc. (NASDAQ: ADGM) is a clinical‐stage medical device company dedicated to developing minimally invasive therapies for structural heart disease. The company’s core focus lies in designing catheter‐based solutions that address conditions such as mitral regurgitation and thromboembolism risk associated with the left atrial appendage. By leveraging novel implant geometries and low‐profile delivery systems, Adagio Medical aims to provide permanent, durable treatments that can be delivered through minimally invasive access pathways. The company’s lead product candidates include a transseptal mitral annuloplasty system designed to reshape and stabilize the mitral valve annulus, as well as a percutaneous left atrial appendage occluder intended to reduce stroke risk in patients with atrial fibrillation. Both platforms employ nitinol‐based frames and biocompatible sealing membranes that conform to patient‐specific anatomies. These devices are fully retrievable and repositionable prior to final deployment, allowing physicians to optimize placement under real-time imaging guidance. Headquartered in Irvine, California, Adagio Medical conducts its preclinical research and early feasibility studies at major cardiovascular centers across North America and Europe. The company’s manufacturing footprint includes an ISO-certified production facility in Southern California, while its research and development team collaborates closely with leading academic institutions and contract research organizations to advance product design and execute clinical trials. Regulatory engagement efforts are underway in both the United States and European Union, with planned submissions to seek investigational device approvals and CE marking. Adagio Medical is led by a seasoned management team with deep expertise in medical device engineering, regulatory strategy, and interventional cardiology. The board of directors features former executives and clinical investigators from top cardiovascular device companies, ensuring strategic oversight throughout product development and commercialization. As the company progresses its clinical programs, it continues to forge partnerships with key opinion leaders and healthcare institutions to bring next-generation structural heart therapies to patients globally.Written by Jeffrey Neal JohnsonView Adagio Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)America Movil (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.